F Haroun, MD
@Cancer_talks
👨🏫 Hematology & Oncology University of Minnesota (previously at GWU). Thoracic and Head&Neck cancer.
You might like
Sonal Paul, MD, Joins the George Washington University Cancer Center as a Hematologist-Oncologist Welcome to GW Cancer Center, Dr. Paul! bit.ly/3x629E5
Immensely proud of our GW #hemonc fellows. Humbled by their maturity and professionalism, and confident that they will provide patients with the most compassionate and informed care. #graduation @GW_MFA @GWCancer @GWSMHS This group would make any PD proud!
Durvalumab consolidation for pts with limited-stage small-cell lung ca Spigel #lcsm #asco24 The poor prognosis of SCLC even in limited stg disease translated to an OS benefit in the #ADRIATIC mirroring the CASPIAN results. Different SEA similar wave with 10% absolute OS benefit
LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO ➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️ ➡️ 24-mo PFS: 65% vs 13% 📈 ➡️ 81% received osi at progression 💊, Good! ➡️AE discontinuation**: 13% vs 5% ⚠️ Can't wait for @RamalingamMD's presentation today! 🎤 #ASCO24 @OncoAlert Data…
Neoadjuvant nivo plus ipi versus adj nivo in macro, resectable st Ill #melanoma: The phase 3 #NADINA trial #asco24 Dr.Blank Impressive PFS benefit of 2 cycles of neoadjuvant vs a standard of care adj approach. Benefit shorter duration of therapy Negative more iAE with CTLA4
CROWN: Lorlatinib vs Crizotinib in ALK+ NSCLC - 5-Year Follow-Up At 5yrs PFS: Lorlatinib 60% (5-yr) vs Crizotinib 8% Lorlatinib IC DFS >93% with HR0.03 Grade 3/4 AEs: 77% Lorlatinib vs 57% Crizotinib #asco24 #lcsm
Sacituzumab tirumotecan (SKB264/ MK-2870) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC from the phase Il OptiTROP-Lung01 study. Wenfeng Fang, MD, PhD
ICARUS-LUNG01: A phase 2 study of datopotomab deruxtecan (Dato-DXd) in pts with previously treated NSCLC with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. #DavidPlanchard #asco24 #lcsm
Sacituzumab govitecan (SG) vs docetaxel in pts with mNSCLC previously treated with platinum chemo and PD(L)-inhibitors Primary results from the phase 3 EVOKE-01 study OS- no benefit- subgroup may show benefit in patient without a prior response to PD inhibition. #asco24 #lcsm
Back in Chicago for ASCO, excited to see that breakthroughs in lung cancer are dominating the meeting. #asco #asco2024 #lcsm
Thrilled to be part of this amazing talented group of featured voices #ASCO2024 for the third year 🎉 Follow the team for more insight on the most updated conference in Oncology 2024. @HamidMD10 @jacobadashek @TwoOncDocs @DarcyBurbage @fumikochino @DevikaDasMD @ADesaiMD
Announcing the 2024 ASCO Annual Meeting Featured Voices! Follow along for a range of expert insights & join the discussion using the official hashtag: #ASCO24 ⤵️
I welcome the +ve #LAURAIII trial for #Osimertinib post ChemoRT in locally advanced EGFRm NSCLC despite the indefinite indication/design Cure in stage III NSCLC continues to be the aim but isn’t the norm Longterm DFS (🫣OS trend) is a huge step forward. astrazeneca.com/media-centre/p…
A great big high five to Faysal Haroun, MD, for being selected as a top doctor in Washington, DC, by your peers! #topdoc #washingtonian #healthcare #oncologist #cancer #gwcancercenter #topdoctor #WashingtonDC
United States Trends
- 1. #Worlds2025 34K posts
- 2. #TalusLabs N/A
- 3. Raindotgg 1,824 posts
- 4. #T1WIN 24.3K posts
- 5. Doran 13.5K posts
- 6. Sam Houston 1,499 posts
- 7. Oregon State 4,775 posts
- 8. Boots 28.7K posts
- 9. Boots 28.7K posts
- 10. Louisville 14.3K posts
- 11. #GoAvsGo 1,550 posts
- 12. Batum N/A
- 13. Faker 29.3K posts
- 14. #Toonami 2,403 posts
- 15. UCLA 7,797 posts
- 16. Miller Moss 1,230 posts
- 17. Oilers 5,123 posts
- 18. Emmett Johnson 2,513 posts
- 19. Nuss 5,714 posts
- 20. Hyan 1,328 posts
You might like
-
Hossein Borghaei, DO
@HosseinBorghaei -
@gulleyj1
@gulleyj1 -
John P. Leonard, MD
@JohnPLeonardMD -
Joshua Sabari, MD
@JSabari -
Geoff Oxnard MD
@geoff_oxnard -
Benjamin Weinberg, MD, FACP
@benweinbergmd -
Jennifer A. Marks, MD
@jennifermarksmd -
Misako Nagasaka
@MNagasaka -
Chul Kim
@chulkimMD -
Rami Manochakian MD, FASCO Cancer Education
@RManochakian -
Carla Casulo, MD
@DrCarlaCasulo -
Merry-Jennifer Markham, MD, FACP, FASCO
@DrMarkham -
Philippe Aftimos, MD
@aftimosp -
Nathan A. Pennell MD, PhD, FASCO
@n8pennell -
Julie Vose
@DrJulieVose
Something went wrong.
Something went wrong.